The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR Pharmaceuticals for use in up to five of Alexion’s gene therapies.
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M